P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)
Main Authors: | W. Jurczak, A. J. Alencar, G. S. Guru Murthy, M. Hoffmann, J. M. Pagel, V. Patel, J. M. Pauff, P. L. Zinzani, S. Le Gouill, A. R. Mato, L. E. Roeker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845616.77820.49 |
Similar Items
-
P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
by: Michal Kwiatek, et al.
Published: (2023-08-01) -
Bcl-2 inhibition in the treatment of hematologic malignancies
by: John X. Wei, et al.
Published: (2023-12-01) -
P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE
by: T. A. Eyre, et al.
Published: (2022-06-01) -
Roles and Regulation of BCL-xL in Hematological Malignancies
by: Mario Morales-Martínez, et al.
Published: (2022-02-01) -
Bank Islam untung RM683 juta
by: Mohamad Shofi, Mat Isa
Published: (2014)